{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.81","value":"3.3"},{"groupId":"OG001","spread":"7.53","value":"4.4"}]}]}],"denomUnitsSelected":"Number of visits","denoms":[{"counts":[{"groupId":"OG000","value":"461"},{"groupId":"OG001","value":"230"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"545"},{"groupId":"OG001","value":"232"}],"units":"Number of visits"}],"description":"Duration of hospital visit was calculated as = stop date - start date + 1. Mean and standard deviation data for duration of hospital visits (in days) by participants was reported in this outcome measure.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 5 mg of fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG000","title":"Fruquintinib + BSC Group"},{"description":"Participants received placebo matched to fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG001","title":"Placebo + BSC Group"}],"paramType":"MEAN","populationDescription":"ITT population included all randomized participants.","reportingStatus":"POSTED","timeFrame":"From start of study drug administration up to 22 months","title":"Health Care Resource Utilization: Duration of Hospital Visits by Participants","type":"SECONDARY","typeUnitsAnalyzed":"Number of visits","unitOfMeasure":"days per visit"}